Gastrointestinal PCR Assay Offers Rapid, Culture-Free Pathogen Identification
By LabMedica International staff writers Posted on 17 Apr 2023 |
Gastroenteritis involves inflammation of the stomach and intestines' lining, typically characterized by diarrhea and/or vomiting. Gastrointestinal pathogens can cause life-threatening diseases, especially among children, immunosuppressed individuals, and the elderly. While most cases resolve within days, severe or persistent cases may necessitate hospitalization. Testing stool samples for potential causative agents—bacteria, viruses, parasites, and toxins—creates a substantial diagnostic burden in healthcare facilities. Now, a new syndromic panel for gastrointestinal infections that identifies 26 gastroenteritis-causing pathogens, including bacteria, viruses, parasites, and related toxins, aims to streamline routine procedures and enhance diagnostic efficiency.
Bruker Corporation’s (Billerica, MA, USA) new LiquidArray Gastrointestinal is a syndromic panel for gastrointestinal infections. The assay employs LiquidArray, a next-generation multiplexing technology, to detect up to 26 pathogens from stool samples using a two-well format that supports routine laboratory throughput needs. Introduced on the high-precision FluoroCycler XT thermocycler, LiquidArray merges innovative probe and thermocycling technologies with results-at-a-glance visualization for simultaneous analysis of multiple targets from a single sample. The integrated FluoroSoftware XT-IVD generates easy-to-understand results, expediting clinical decisions.
LiquidArray Gastrointestinal is validated on the GenoXtract fleXT, a dependable, automated system for extracting nucleic acid from patient samples and setting up PCR plates. Barcode-supported robotic sorting minimizes manual intervention. Validated processing of LiquidArray Gastrointestinal on the GenoXtract fleXT offers a convenient walk-away solution tailored for dynamic laboratory environments. This equips high-throughput clinical labs with a fully integrated workflow from sample to result. The test is validated for use with stool samples, and a stool buffer developed for LiquidArray Gastrointestinal enables stabilization and storage of samples to be tested. The kit includes reagents for up to 48 reactions.
“The new LiquidArray Gastrointestinal is a next-generation syndromic panel with amazing pathogen coverage. It is ideal for laboratories which are interested in a broad screening approach to detect most pathogens in one run,” said Dr. Wolfgang Pusch, President of the Bruker Microbiology & Infection Diagnostics division.
Related Links:
Bruker Corporation
Latest Microbiology News
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia
- Rapid AST Platform Provides Targeted Therapeutic Results Days Faster Than Current Standard of Care
- New Analysis Method Detects Pathogens in Blood Faster and More Accurately by Melting DNA
- Rapid Sepsis Test Delivers Two Days Faster Results
- Portable Rapid PCR Diagnostic to Detect Gonorrhea and Antibiotic Susceptibility